Keyphrases
Clinical Outcomes
100%
Previously Treated
100%
Advanced Hepatocellular Carcinoma
100%
Lenvatinib
100%
Atezolizumab Plus Bevacizumab
100%
Anorexia
44%
Adverse Events
33%
General Fatigue
22%
Bevacizumab Treatment
22%
No Significant Difference
11%
Therapeutic Benefits
11%
Clinical Efficacy
11%
Hepatocellular Carcinoma
11%
Overall Survival
11%
Median Overall Survival
11%
Median Progression-free Survival
11%
Progression-free Survival
11%
Response Evaluation Criteria in Solid Tumors (RECIST)
11%
Objective Response Rate
11%
Disease Control Rate
11%
First-line Therapy
11%
Hepatocellular Carcinoma Patients
11%
Treatment Outcome
11%
Rate Control
11%
Molecular Targeted Agents
11%
Drug Discontinuation
11%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Liver Cell Carcinoma
100%
Lenvatinib
100%
Atezolizumab
100%
Anorexia
44%
Adverse Event
33%
Overall Survival
22%
Progression Free Survival
22%
Disease
11%
Solid Malignant Neoplasm
11%
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Bevacizumab
100%
Lenvatinib
100%
Atezolizumab
100%
Anorexia
44%
Adverse Event
33%
Overall Survival
22%
Progression Free Survival
22%
Disease
11%
Response Evaluation Criteria in Solid Tumors
11%